Secukinumab in plaque psoriasis--results of two phase 3 trials.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Interleukin-17A is considered to be central to the pathogenesis of psoriasis. We evaluated secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe plaque psoriasis.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): N Engl J Med

Title: The New England journal of medicine

Publisher: Massachusetts Medical Society

ISSN (Electronic): 1533-4406

ISSN (Print): 0028-4793

Publication date (Electronic): Jul 24 2014

Volume: 371

Issue: 4

Affiliations

[1 ] From Dalhousie University, Halifax, NS (R.G.L.), Clinical Research (K.P.) and Probity Medical Research (K.P., L.S.), Waterloo, ON, and Stratica Medical and Probity Medical Research, Edmonton, AB (N.W.) - all in Canada; University of Alabama, Birmingham (B.E.E.); Mount Sinai Hospital, New York (M.L.); Dermatologikum Hamburg and Georg-August-Universität, Göttingen, Germany (K.R.); Dermatology Centre, Salford Royal Hospital, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom (C.E.M.G.); Hospital de Sant Pau, Barcelona (L.P.); Jikei University School of Medicine, Tokyo (H.N.); Veracity Clinical Research, Woolloongabba, QLD, Australia (L.S.); Faculty of Medicine, Department of Dermatology, University of Iceland, Reykjavik (B.S.); Dermos, Guatemala City, Guatemala (E.R.); Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei (T.-F.T.); University of Texas Health Science Center and Center for Clinical Studies, Houston (S.T.); and Novartis Pharma, Basel, Switzerland (T.S., I.H., M.N., A.K., S.H., C.P.).

Article

DOI: 10.1056/NEJMoa1314258

PubMed ID: 25007392

SO-VID: 1d38904a-4de1-45f5-a253-11116478d27a

History

Data availability:

Comments

Comment on this article

scite_

Cited by 585

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Authors: Dan L Longo, Michael A. Postow, Robert Sidlow …
Psoriasis.
Authors: Wolf-Henning Boehncke, Michael P. Schön
Psoriasis Pathogenesis and Treatment
Authors: Adriana Rendon, Knut Schäkel

See all cited by

- Version 1